EGFR and non-small cell lung carcinoma: The third-generation covalent and mutant-selective EGFR TKIs rociletinib (CO-1686)12 and osimertinib (AZD9291)13 target both activating and T790M mutations, and have demonstrated activity in T790M-positive NSCLC patients14, 15.